CG Oncology, Inc. Common stock (CGON)vsRevolution Medicines Inc (RVMD)
CGON
CG Oncology, Inc. Common stock
$53.72
-4.23%
HEALTHCARE · Cap: $5.25B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
CG Oncology, Inc. Common stock generates 583% more annual revenue ($5.07M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CGON earns a higher WallStSmart Score of 34/100 (F).
CGON
Avoid34
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
CGON generates stronger free cash flow (-57M), providing more financial flexibility.
Bottom Line
CGON scores higher overall (34/100 vs 24/100) and 1983.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing pioneering cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. Committed to addressing significant unmet medical needs in the oncology space, the company is well-positioned to enhance patient outcomes and transform existing treatment paradigms. As CG Oncology progresses through clinical trials and regulatory processes, its proprietary technology platform sets it apart in the competitive oncology landscape, presenting compelling investment opportunities for institutional investors keen on advancing innovations that may substantially influence cancer care.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?